No association between BMI and immunotoxicity or clinical outcomes for immune checkpoint inhibitors

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Cortellini A, Ricciuti B, Tiseo M et al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. J. Immunother. Cancer 8(2), e001403 (2020).
  MedlineGoogle Scholar
• 2. Cortellini A, Bersanelli M, Buti S et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J. Immunother. Cancer 7(1), 57 (2019).
  MedlineGoogle Scholar
• 3. Rogado J, Romero-Laorden N, Sanchez-Torres JM et al. Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. Oncoimmunology 9(1), 1751548 (2020).
  MedlineGoogle Scholar
• 4. Richtig G, Hoeller C, Wolf M et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study. PLoS One 13(10), e0204729 (2018).
  MedlineGoogle Scholar
• 5. Jin J, Stabile LP. When fat is favorable: the unexpected relationship between obesity and response to immunotherapy. Immunotherapy 12(14), 1035–1039 (2020).
  CASGoogle Scholar
• 6. Nie RC, Chen GM, Wang Y et al. Association between body mass index and survival outcomes in patients treated with immune checkpoint inhibitors: meta-analyses of individual patient data. J. Immunother. 44(9), 371–375 (2021).
  Medline CASGoogle Scholar
• 7. Francisco V, Pino J, Campos-Cabaleiro V et al. Obesity, fat mass and immune system: role for leptin. Front. Physiol. 9, 640 (2018).
  MedlineGoogle Scholar
• 8. Wang Z, Aguilar EG, Luna JI et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat. Med. 25(1), 141–151 (2019).
  Medline CASGoogle Scholar
• 9. Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J. Clin. Oncol. 34(35), 4270–4276 (2016).
  Medline CASGoogle Scholar
• 10. Johannet P, Sawyers A, Qian Y et al. Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J. Immunother. Cancer 8(2), e001674 (2020).
  MedlineGoogle Scholar
• 11. Young AC, Quach HT, Song H et al. Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma. J. Immunother. Cancer 8(2), e000821 (2020).
  MedlineGoogle Scholar
• 12. De Giorgi U, Procopio G, Giannarelli D et al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin. Cancer Res. 25(13), 3839–3846 (2019).
  MedlineGoogle Scholar
• 13. Popinat G, Cousse S, Goldfarb L et al. Subcutaneous fat mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab. Oncoimmunology 8(5), e1580128 (2019).
  MedlineGoogle Scholar
• 14. Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 18(1), 87 (2020).
  Medline CASGoogle Scholar
• 15. Cortellini A, Bersanelli M, Santini D et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur. J. Cancer 128, 17–26 (2020). •• Largest (n = 1070) study to date to report a positive association between high BMI and immune-related adverse events (irAEs), overall survival (OS) and progression-free survival.
  Medline CASGoogle Scholar
• 16. McQuade JL, Daniel CR, Hess KR et al. Association of body mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 19(3), 310–322 (2018).
  MedlineGoogle Scholar
• 17. Caan BJ, Meyerhardt JA, Kroenke CH et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS study). Cancer Epidemiol. Biomarkers Prev. 26(7), 1008–1015 (2017). • Includes a histogram that illustrates the heterogeneous nature of body composition phenotypes by BMI from a large cohort of colorectal cancer patients, especially in the overweight (BMI 25–30) category.
  MedlineGoogle Scholar
• 18. NIH. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (2021). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
  Google Scholar
• 19. Labadie BW, Liu P, Bao R et al. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. J. Transl. Med. 17(1), 386 (2019).
  Medline CASGoogle Scholar
• 20. Indini A, Rijavec E, Ghidini M et al. Impact of BMI on survival outcomes of immunotherapy in solid tumors: a systematic review. Int. J. Mol. Sci. 22(5), 2628 (2021).
  Medline CASGoogle Scholar
• 21. Eun Y, Kim IY, Sun JM et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci. Rep. 9(1), 14039 (2019).
  MedlineGoogle Scholar
• 22. Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol. 6(4), 512–518 (2020). •• Largest (n = 1434) study on the association between BMI and non-small-cell lung cancer outcomes, which also reported negative results with respect to irAEs (though statistically significant association with OS).
  MedlineGoogle Scholar
• 23. Ichihara E, Harada D, Inoue K et al. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer 139, 140–145 (2020).
  MedlineGoogle Scholar
• 24. Martini DJ, Liu Y, Shabto JM et al. Novel risk scoring system for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist 25(3), e484–e491 (2020).
  Medline CASGoogle Scholar
• 25. Martini DJ, Kline MR, Liu Y et al. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer 126(3), 575–582 (2020).
  Medline CASGoogle Scholar
• 26. Takada K, Takamori S, Yoneshima Y et al. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer 145, 18–26 (2020).
  MedlineGoogle Scholar
• 27. Lalani AA, Bakouny Z, Farah S et al. Assessment of Immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma. JAMA Oncol. 7(5), 773–775 (2021).
  MedlineGoogle Scholar
• 28. Daly LE, Power DG, O'Reilly A et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br. J. Cancer 116(3), 310–317 (2017).
  Medline CASGoogle Scholar
• 29. Rutkowski P, Indini A, De Luca M et al. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. J. Immunother. Cancer 8(2), e001117 (2020).
  MedlineGoogle Scholar
• 30. Donnelly D, Bajaj S, Yu J et al. The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients. J. Immunother. Cancer 7(1), 222 (2019).
  MedlineGoogle Scholar
• 31. Shiroyama T, Suzuki H, Tamiya M et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med. 7(1), 13–20 (2018).
  Medline CASGoogle Scholar
• 32. Rassy EE, Ghosn M, Rassy NA, Assi T, Robert C. Do immune checkpoint inhibitors perform identically in patients with weight extremes? Immunotherapy 10(9), 733–736 (2018).
  CASGoogle Scholar
• 33. Chen H, Wang D, Zhong Q, Tao Y, Zhou Y, Shi Y. Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol. Immunother. 69(12), 2413–2424 (2020). • One of three large meta-analyses evaluating BMI and immunotoxicity that found no difference for any grade irAEs or grade ≥3 irAEs.
  Medline CASGoogle Scholar
• 34. An Y, Wu Z, Wang N et al. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J. Transl. Med. 18(1), 235 (2020).
  MedlineGoogle Scholar
• 35. Guzman-Prado Y, Ben Shimol J, Samson O. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis. Cancer Immunol. Immunother. 70(1), 89–100 (2021). • Only meta-analysis reporting a statistically significant relationship between high BMI and irAE development.
  MedlineGoogle Scholar
• 36. Hsiehchen D, Watters MK, Lu R, Xie Y, Gerber DE. Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors. JAMA Netw. Open 2(9), e1911519 (2019).
  MedlineGoogle Scholar
• 37. Sanchez A, Furberg H, Kuo F et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol. 21(2), 283–293 (2020).
  Medline CASGoogle Scholar
• 38. Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins JT. The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. Eur. J. Surg. Oncol. 41(2), 186–196 (2015).
  Medline CASGoogle Scholar
• 39. Naik GS, Waikar SS, Johnson AEW et al. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J. Immunother. Cancer 7(1), 89 (2019).
  MedlineGoogle Scholar
• 40. Freshwater T, Kondic A, Ahamadi M et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J. Immunother. Cancer 5, 43 (2017).
  MedlineGoogle Scholar
• 41. Walker S, Leseleuc L, Butcher R. CADTH technology review: optimal use 360 report: dosing and timing of immuno-oncology drugs (2019). www.cadth.ca/sites/default/files/ou-tr/ho0008-dosing-timing-immuno-oncology-drugs.pdf
  Google Scholar
• 42. Finelli C. Obesity and immunotherapy: the surprisingly positive association! Immunotherapy 12(8), 541–544 (2020).
  CASGoogle Scholar
• 43. Bergerot PG, Bergerot CD, Philip EJ et al. Targeted therapy and immunotherapy: effect of body mass index on clinical outcomes in patients diagnosed with metastatic renal cell carcinoma. Kidney Cancer 3(1), 63–70 (2019).
  CASGoogle Scholar